The Journal of Heart and Lung Transplantation
Volume 29, Issue 12 , Pages 1395-1404, December 2010

Lung transplantation for patients with cystic fibrosis and Burkholderia cepacia complex infection: A single-center experience

  • Anthony De Soyza, PhD, MbChB

      Affiliations

    • Transplantation and Immunobiology Group, Institute of Cellular Medicine, Newcastle University, Newcastle-upon-Tyne, UK
    • Corresponding Author InformationReprint requests: Anthony De Soyza, PhD, MbChB, Transplantation and Immunology Group, Newcastle University, Institute of Cellular Medicine, High Heaton, Newcastle-upon-Tyne NE7 7DN, UK. Telephone: 00-44-191-2137468. Fax: 00-44-191-2137087
  • ,
  • Gerard Meachery, MBBCh, MRCP

      Affiliations

    • Department of Cardiopulmonary Transplantation, The Freeman Hospital, Newcastle-upon-Tyne, UK
  • ,
  • Katy L.M. Hester, MBBS

      Affiliations

    • Department of Cardiopulmonary Transplantation, The Freeman Hospital, Newcastle-upon-Tyne, UK
  • ,
  • Audrey Nicholson, MSc

      Affiliations

    • Department of Medical Microbiology, The Freeman Hospital, Newcastle-upon-Tyne, UK
  • ,
  • Gareth Parry, FRCP

      Affiliations

    • Department of Cardiopulmonary Transplantation, The Freeman Hospital, Newcastle-upon-Tyne, UK
  • ,
  • Krzysztof Tocewicz, FRCS

      Affiliations

    • Department of Cardiopulmonary Transplantation, The Freeman Hospital, Newcastle-upon-Tyne, UK
  • ,
  • Thasee Pillay, MbChB, FCS(CTh)FRCS

      Affiliations

    • Department of Cardiopulmonary Transplantation, The Freeman Hospital, Newcastle-upon-Tyne, UK
  • ,
  • Stephen Clark, FRCS

      Affiliations

    • Department of Cardiopulmonary Transplantation, The Freeman Hospital, Newcastle-upon-Tyne, UK
  • ,
  • James L. Lordan, FRCP

      Affiliations

    • Department of Cardiopulmonary Transplantation, The Freeman Hospital, Newcastle-upon-Tyne, UK
  • ,
  • Stephan Schueler, MD, PhD, FRCS

      Affiliations

    • Department of Cardiopulmonary Transplantation, The Freeman Hospital, Newcastle-upon-Tyne, UK
  • ,
  • Andrew J. Fisher, MBBS, PhD, FRCP

      Affiliations

    • Transplantation and Immunobiology Group, Institute of Cellular Medicine, Newcastle University, Newcastle-upon-Tyne, UK
    • Department of Cardiopulmonary Transplantation, The Freeman Hospital, Newcastle-upon-Tyne, UK
  • ,
  • John H. Dark, FRCS

      Affiliations

    • Department of Cardiopulmonary Transplantation, The Freeman Hospital, Newcastle-upon-Tyne, UK
  • ,
  • F. Kate Gould, FRC(Path)

      Affiliations

    • Department of Cardiopulmonary Transplantation, The Freeman Hospital, Newcastle-upon-Tyne, UK
    • Department of Medical Microbiology, The Freeman Hospital, Newcastle-upon-Tyne, UK
  • ,
  • Paul A. Corris, FRCP

      Affiliations

    • Transplantation and Immunobiology Group, Institute of Cellular Medicine, Newcastle University, Newcastle-upon-Tyne, UK
    • Department of Cardiopulmonary Transplantation, The Freeman Hospital, Newcastle-upon-Tyne, UK

published online 02 September 2010.

Background

Pre-operative infection with organisms from the Burkholderia cepacia complex (BCC), particularly B cenocepacia, has been linked with a poorer prognosis after transplantation compared to patients with cystic fibrosis (CF) without this infection. Therefore, many transplant centers do not list these patients for transplantation.

Methods

We report the early and long-term results of a cohort of lung transplant recipients with CF and pre-operative BCC infection. Patients with pre-transplantation BCC infection were identified by case-note review. BCC species status was assigned by polymerase chain reaction (PCR)-based techniques. Survival rates were compared to recipients with CF without BCC infection. Survival rates in BCC subgroups were also compared, and then further analyzed pre- and post-2001, when a new immunosuppressive and antibiotic regime was introduced for such patients.

Results

Two hundred sixteen patients with CF underwent lung transplantation and 22 had confirmed pre-operative BCC infection, with 12 of these being B cenocepacia. Nine B cenocepacia–infected recipients died within the first year, and in 8 BCC sepsis was considered to be the cause of death. Despite instituting a tailored peri-operative immunosuppressive and microbiologic care approach for such patients, post-transplantation BCC septic deaths occurred frequently in those with pre-transplantation B cenocepacia infection. In contrast, recipients infected with other BCC species had significantly better outcomes, with post-transplantation survival comparable to other recipients with CF.

Conclusions

Mortality in patients with B cenocepacia infection was unacceptably high and has led to our center no longer accepting patients with this condition onto the lung transplant waiting list. Long-term survival in the non–B cenocepacia BCC group was excellent, without high rates of acute rejection or bronchiolitis obliterans syndrome (BOS) longer term, and these patients continue to be considered for lung transplantation.

Keywords: cystic fibrosis, Burkholderia cepacia complex, genomovar, lung transplantation, survival

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.
 

PII: S1053-2498(10)00370-0

doi:10.1016/j.healun.2010.06.007

The Journal of Heart and Lung Transplantation
Volume 29, Issue 12 , Pages 1395-1404, December 2010